Mentors like Mizell sparked Paul’s interest in the biological bases for central nervous system (CNS) and psychiatric illnesses. Paul holds a bachelor’s from Tulane and an MS and MD from Tulane University School of Medicine. His first scientific paper was co-authored with Mizell while Paul was still an undergraduate.

Now, Paul is president and CEO of Voyager Therapeutics, a clinical-stage gene therapy company, as well as founder and director of SAGE Therapeutics. He helps develop life-changing gene therapies for severe CNS diseases such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease and Huntington’s disease. Armed with his knowledge from Tulane, he works every day to solve the mysteries of the brain.